RENAL MEDULLARY CARCINOMA
Clinical trials for RENAL MEDULLARY CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RENAL MEDULLARY CARCINOMA trials appear
Sign up with your email to follow new studies for RENAL MEDULLARY CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets rare childhood and adult cancers
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults with rare cancers that have come back or not responded to treatment. These cancers lack certain genes (SMARCB1 or SMARCA4), making them hard to treat. The goal is to see if the drug com…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy targets rare, aggressive kidney cancer
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and relatlimab, can shrink or control a rare and aggressive kidney cancer called renal medullary carcinoma (RMC). The trial includes 30 adults whose cancer has spread or cannot be removed by surgery. The goal is to see h…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis phase II trial is testing whether combining the targeted drug ixazomib with two chemotherapy drugs (gemcitabine and doxorubicin) can shrink tumors or stop them from growing in patients with a rare and aggressive kidney cancer called renal medullary carcinoma. The study enrol…
Matched conditions: RENAL MEDULLARY CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC